Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®, a new CIS-Demasking 1 cytokine ...

The healthcare sector was a notable outlier early Thursday as markets plummeted on tariff shock. But there are signs of ...

Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...

In Forbes‘ World’s Billionaires list, released April 1, highlights the world’s wealthiest individuals. Below is a breakdown ...

BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...

Shares of early-stage biotech stocks, including Biohaven ( BHVN -6.50%), Recursion Pharmaceuticals ( RXRX -7.37%), and CRISPR ...

Bo Wang is a renowned AI scientist at the University of Toronto. He’s bringing his open-source culture and computational ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in patients with untreated NSCLC.